Evotec SE, DE0005664809

Evotec SE, DE0005664809

09.11.2022 - 07:03:34

EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update

The forecast takes in account ? as far as possible ? the current increased global uncertainties related to e.g., the COVID-19 pandemic and the war in Ukraine, resulting in uncertainty around the global price and supply situation for energy, other raw materials and supplies as well as logistics relevant to the business. M&A related costs have not been part of the initial guidance and will therefore be excluded.

? ?

FINANCIAL HIGHLIGHTS

The following table provides an overview of the financial performance in the first nine months of 2022 compared to the same period in 2021.

?

Key figures of consolidated income statement & segment informationEvotec SE & subsidiaries ? First nine months of 2022

??In T? EVTExecute EVTInnovate ?Intersegment Eliminations Evotec Group9M 2022 Evotec Group9M 2021 Revenues1) 388,828 121,931 ? 510,759 430,963 Intersegment revenues 137,876 ? ?(137,876) ? ? Costs of revenues ?(441,332) ?(104,578) 126,760 (419,150) (331,494) Gross profit 85,372 17,353 ?(11,116) 91,609 99,469 Gross margin in % 16.2 14.2 ? 17.9 23.1 ? ? ? ? ? ? R&D expenses2) ?(4,231) ?(62,206) 11,116 ?(55,321) ?(53,472) SG&A expenses ?(88,178) ?(21,680) ? ?(109,858) ?(71,037) Impairments of intangible assets ? ? ? ? (683) Other operating income (expenses), net ? 25,288 ? 31,446 ? ? ? 56,734 ? 51,776 Net operating income (loss) 18,251 (35,087) ? (16,836) 26,053 ? ? ? ? ? ? Adjusted EBITDA3) 75,826 (31,226) ? 44,600 70,086

1) Adjusted for exchange rate effects of ??26.1?m, Group revenues would have amounted to ??484.6?m

2) Includes unpartnered R&D expenses of ??50.7?m in 9M?2022 (9M?2021: ??42.6?m)

3) Before changes in contingent consideration, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

WEBCAST / CONFERENCE CALL

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

?

Conference call details

Date: ???Wednesday, 09 November 2022 Time: ???02.00 pm CET (08.00 am EDT, 01.00 pm BST)

To join via phone, please pre-register via the following link: http://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=8321512&linkSecurityString=9c554f538

You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20221109/no-audio.

?

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications.ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company?s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this ?Data-driven R&D Autobahn to Cures? for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company?s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec?s securities. Words such as ?anticipate,? ?believe,? ?could,? ?estimate,? ?expect,? ?intend,? ?may,? ?might,? ?plan,? ?potential,? ?should,? ?target,? ?would? and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec?s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec?s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Media Contact Evotec SE: Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com Hinnerk Rohwedder, Senior Specialist Corporate Communications, Tel.: +49.(0)151 4070-4843, hinnerk.rohwedder@evotec.comIR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

09.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg

Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1482549 ? End of News EQS News Service

1482549??09.11.2022?CET/CEST

@ dgap.de